
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Q The mother of an 8-year-old girl in my practice, who describes herself as having been "very sensitive" ever since she was a child, mentioned to me that her daughter has recently adopted what she calls an "uncaring attitude" about the health and well-being of her family.






